Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund Form N-CSRS August 22, 2008

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT INVESTMENT COMPANIES

Investment Company Act file number 811-21745

Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund (Exact name of registrant as specified in charter)

The Eaton Vance Building, 255 State Street, Boston, Massachusetts (Address of principal executive offices)

02109 (Zip code)

Maureen A. Gemma

The Eaton Vance Building, 255 State Street, Boston, Massachusetts 02109 (Name and address of agent for service)

Registrant s telephone number, including area code: (617) 482-8260

Date of fiscal year December 31 end:

Date of reporting period: June 30, 2008

Item 1. Reports to Stockholders

Semiannual Report June 30, 2008

EATON VANCE TAX-MANAGED GLOBAL BUY-WRITE OPPORTUNITIES FUND

IMPORTANT NOTICES REGARDING PRIVACY, DELIVERY OF SHAREHOLDER DOCUMENTS, PORTFOLIO HOLDINGS AND PROXY VOTING

Privacy. The Eaton Vance organization is committed to ensuring your financial privacy. Each of the financial institutions identified below has in effect the following policy ("Privacy Policy") with respect to nonpublic personal information about its customers:

Only such information received from you, through application forms or otherwise, and information about your Eaton Vance fund transactions will be collected. This may include information such as name, address, social security number, tax status, account balances and transactions.

None of such information about you (or former customers) will be disclosed to anyone, except as permitted by law (which includes disclosure to employees necessary to service your account). In the normal course of servicing a customer's account, Eaton Vance may share information with unaffiliated third parties that perform various required services such as transfer agents, custodians and broker/dealers.

Policies and procedures (including physical, electronic and procedural safeguards) are in place that are designed to protect the confidentiality of such information.

We reserve the right to change our Privacy Policy at any time upon proper notification to you. Customers may want to review our Policy periodically for changes by accessing the link on our homepage: www.eatonvance.com.

Our pledge of privacy applies to the following entities within the Eaton Vance organization: the Eaton Vance Family of Funds, Eaton Vance Management, Eaton Vance Investment Counsel, Boston Management and Research, and Eaton Vance Distributors, Inc.

In addition, our Privacy Policy only applies to those Eaton Vance customers who are individuals and who have a direct relationship with us. If a customer's account (i.e., fund shares) is held in the name of a third-party financial adviser/broker-dealer, it is likely that only such adviser's privacy policies apply to the customer. This notice supersedes all previously issued privacy disclosures.

For more information about Eaton Vance's Privacy Policy, please call 1-800-262-1122.

Delivery of Shareholder Documents. The Securities and Exchange Commission (the "SEC")permits funds to deliver only one copy of shareholder documents, including prospectuses, proxy statements and shareholder reports, to fund investors with multiple accounts at the same residential or post office box address. This practice is often called "householding" and it helps eliminate duplicate mailings to shareholders.

Eaton Vance, or your financial adviser, may household the mailing of your documents indefinitely unless you instruct Eaton Vance, or your financial adviser, otherwise.

If you would prefer that your Eaton Vance documents not be householded, please contact Eaton Vance at 1-800-262-1122, or contact your financial adviser.

Your instructions that householding not apply to delivery of your Eaton Vance documents will be effective within 30 days of receipt by Eaton Vance or your financial adviser.

Portfolio Holdings. Each Eaton Vance Fund and its underlying Portfolio (if applicable) will file a schedule of its portfolio holdings on Form N-Q with the SEC for the first and third quarters of each fiscal year. The Form N-Q will be available on the Eaton Vance website www.eatonvance.com, by calling Eaton Vance at 1-800-262-1122 or in the EDGAR database on the SEC's website at www.sec.gov. Form N-Q may also be reviewed and copied at the SEC's public reference room in Washington, D.C. (call 1-800-732-0330 for information on the operation of the public reference room).

Proxy Voting. From time to time, funds are required to vote proxies related to the securities held by the funds. The Eaton Vance Funds or their underlying Portfolios (if applicable) vote proxies according to a set of policies and procedures approved by the Funds' and Portfolios' Boards. You may obtain a description of these policies and procedures and information on how the Funds or Portfolios voted proxies relating to portfolio securities during the most recent 12 month period ended June 30, without charge, upon request, by calling 1-800-262-1122. This description is also available on the SEC's website at www.sec.gov.

Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund as of June 30, 2008

INVESTMENT UPDATE

Walter A. Row, CFA Eaton Vance Management Co-Portfolio Manager

Thomas Seto Parametric Portfolio Associates LLC Co-Portfolio Manager

Ronald M. Egalka Rampart Investment Management Co-Portfolio Manager David Stein, Ph.D. Parametric Portfolio Associates LLC Co-Portfolio Manager

Economic and Market Conditions

• Equity markets remained challenging during the first half of the year, as concerns surrounding ailing credit markets, elevated commodity prices and a slowing global economy failed to abate. The equity markets suffered their worst quarterly loss in more than five years in the first quarter of 2008. The second quarter remained difficult, as investors dealt with ongoing turmoil in the financial and housing markets, creeping inflation and a continuing global economic slowdown. Major indices registered declines in the first half of the year, and the S&P 500 Index a common gauge of U.S. domestic markets lost 11.9% during the period. In this environment, small-cap stocks continued to lead large-cap stocks, and growth stocks outpaced their value counterparts. Foreign markets, as represented by the Morgan Stanley Capital International Europe, Far East and Australasia Index, registered declines in the first half of 2008. In Europe, markets fell under the weight of rising oil prices, higher inflation and declining corporate profits. The Japanese market also posted negative returns, as investors reacted to rising energy costs, continuing losses in the financial sector and concerns that a stronger Yen could hurt Japan s exports of consumer electronics.

• The S&P 500 Index s sector performance varied widely during the period, with commodity-linked energy and materials sectors faring the best and registering the Index s only positive sector returns. The weakest-performing sectors were financials, telecommunication services and industrials. Index-leading industries during the period included energy equipment and services, gas utilities, road and rail, and metals and mining. In contrast, industries such as thrift and mortgage finance, automobiles, health care providers, and diversified financials were among the period s worst performers.

Management Discussion

• The Fund s primary objective is to provide current income and gains, with a secondary objective of capital appreciation. The Fund pursues its investment objectives by investing in a diversified portfolio of common stocks, including stocks of U.S. issuers (the U.S. Segment) and stocks of non-U.S. issuers (the International Segment). Under normal market conditions, the Fund seeks to generate current earnings in part by employing an options strategy of writing index call options on a substantial portion of the value of the Fund s total investments. During the six months ended June 30, 2008, the Fund continued to provide shareholders with attractive quarterly distributions.

Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund

Total Return Performance 12/31/07 6/30/08

NYSE Symbol]	ETW
At Net Asset Value (NAV)			-6.96%
At Market			-4.94%
S&P 500 Index(1)			-11.90%
CBOE S&P 500 Buy-Write Index(1)			-5.89%
CBOE NASDAQ 100 Buy-Write Index(1)			-10.00%
FTSE Eurotop 100 Index(1)			-11.40%
Lipper Options Arbitrage/Options Strategies Average(1)			-7.90%
Total Distributions per share		\$	0.900
Distribution Rate(2)	On NAV		10.40%
	On Market		11.54%

See page 3 for more performance information.

(2) The Distribution Rate is based on the Fund s most recent quarterly distribution per share (annualized) divided by the Fund s NAV or market price at the end of the period. The Fund s quarterly distributions may be comprised of ordinary income, net realized capital gains and return of capital.

Past performance is no guarantee of future results. Returns are historical and are calculated by determining the percentage change in net asset value or share price (as applicable) with all distributions reinvested. The Fund s performance at market share price will differ from its results at NAV. Although share price performance generally reflects investment results over time, during shorter periods, returns at share price can also be affected by factors such as changing perceptions about the Fund, market conditions, fluctuations in supply and demand for the Fund s shares, or changes in Fund distributions. The Fund has no current intention to utilize leverage, but may do so in the future through borrowings and/or other permitted methods. Investment return and principal value will fluctuate so that shares, when sold, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund s current performance may be lower or higher than quoted return. For performance as of the most recent month end, please refer to www.eatonvance.com.

Fund shares are not insured by the FDIC and are not deposits or other obligations of, or guaranteed by, any depository institution. Shares are subject to investment risks, including possible loss of principal invested.

⁽¹⁾ It is not possible to invest directly in an Index or a Lipper Classification. The Indices total returns do not reflect commissions or expenses that would have been incurred if an investor individually purchased or sold the securities represented in the Indices. The return for the FTSE Eurotop 100 Index is calculated in U.S. dollars. The Lipper total return is the average total return, at net asset value, of the funds that are in the same Lipper Classification as the Fund.

INVESTMENT UPDATE

• At net asset value (NAV), the Fund outperformed the S&P 500 Index, the CBOE NASDAQ 100 Buy-Write Index and the FTSE Eurotop 100 Index, while under-performing the CBOE S&P 500 Buy-Write Index for the six months ended June 30, 2008. In a continued volatile market environment, the Fund s market share price like some other closed-end funds traded at a discount to NAV, as investors responded with caution to increasing market volatility. At June 30, 2008, the discount was 9.8%. At June 30, 2008, the Fund held a diversified portfolio encompassing a broad range of the U.S. economy, as well as investments in a variety of foreign countries. The Fund s investments in the U.S. Segment constituted approximately 52% of total investments. The Fund s investments in the International Segment represented approximately 48% of total investments. The majority of the Fund s non-U.S. investments were divided between European markets and Japan. Among the Fund s common stock holdings, its largest sector weightings at June 30, 2008 were information technology, financials, health care, energy and industrials.

• At June 30, 2008, the Fund had written call options on 99.6% of its equity holdings. The Fund seeks current earnings from option premiums, which may vary with investors expectation of the future volatility of the underlying asset. The first six months of 2008 witnessed continued higher levels of volatility in the equity markets. Surging oil prices and continued softness in the housing sector coupled with concerns about regional banks and an increasing anxiety about a possible recession led to dismal equity performance in the first half of the year. While there were fits and starts in the first four months of the year, implied volatility , or the expectation of future volatility, spiked almost 50% in the last six weeks of the second quarter as the broad market averages, measured by the S&P 500 Index, declined 10%. This resulted in a significant boost to option premiums, which provided a positive benefit to the Fund. Of course, in future periods of strong market growth, this strategy may lessen returns relative to the market.

The views expressed throughout this report are those of the portfolio managers and are current only through the end of the period of the report as stated on the cover. These views are subject to change at any time based upon market or other conditions, and the investment adviser disclaims any responsibility to update such views. These views may not be relied on as investment advice and, because investment decisions for a fund are based on many factors, may not be relied on as an indication of trading intent on behalf of any Eaton Vance fund. Portfolio information provided in the report may not be representative of the Fund s current or future investments and may change due to active management.

2

FUND PERFORMANCE

Fund performance

NYSE Symbol	ETW
Average Annual Total Returns (by share price, New York Stock Exchange)	
Six Months	-4.94%
One Year	-10.69
Life of Fund (9/30/05)	2.51
Average Annual Total Returns (at net asset value)	
Six Months	-6.96%
One Year	-3.83
Life of Fund (9/30/05)	6.43

Fund Composition

Top Ten Holdings(1)

By total investments

	2.00
Apple, Inc.	3.8%
Microsoft Corp.	2.1
QUALCOMM, Inc.	1.8
Google, Inc., Class A	1.7
Total SA	1.6
Exxon Mobil Corp.	1.5
Nestle SA	1.4
HSBC Holdings PLC	1.3
Gilead Sciences, Inc.	1.3
Cisco Systems, Inc.	1.3

⁽¹⁾ Top Ten Holdings represented 17.8% of the Fund s total investments as of 6/30/08. The Top Ten Holdings are presented without the offsetting effect of the Fund s written option positions at 6/30/08. Excludes cash equivalents.

Sector Weightings(2)

Past performance is no guarantee of future results. Returns are historical and are calculated by determining the percentage change in net asset value or share price (as applicable) with all distributions reinvested. The Fund s performance at market share price will differ from its results at NAV. Although share price performance generally reflects investment results over time, during shorter periods, returns at share price can also be affected by factors such as changing perceptions about the Fund, market conditions, fluctuations in supply and demand for the Fund s shares, or changes in Fund distributions. The Fund has no current intention to utilize leverage, but may do so in the future through borrowings and/or other permitted methods. Investment return and principal value will fluctuate so that shares, when sold, may be worth more or less than their original cost. Performance is for the stated time period only; due to market volatility, the Fund s current performance may be lower or higher than the quoted return. For performance as of the most recent month end, please refer to www.eatonvance.com.

⁽²⁾ Reflects the Fund s total investments as of 6/30/08. Sector Weightings are presented without the offsetting effect of the Fund s written option positions at 6/30/08. Excludes cash equivalents.

³

PORTFOLIO OF INVESTMENTS (Unaudited)

Common Stocks 99.7%		
Security	Shares	Value
Aerospace & Defense 0.9%		
Finmeccanica SpA	30,000	\$ 784,926
General Dynamics Corp.	78,611	6,619,046
Honeywell International, Inc.	106,620	5,360,854
Rockwell Collins, Inc.	59,584	2,857,649
		\$ 15,622,475
Air Freight & Logistics 0.9%		
CH Robinson Worldwide, Inc.	84,275	\$ 4,621,641
Deutsche Post AG	241,842	6,318,684
Expeditors International of Washington, Inc.	60,642	2,607,606
FedEx Corp.	28,786	2,268,049
Yamato Holdings Co., Ltd.	64,701	904,690
		\$ 16,720,670
Airlines 0.0%		
Japan Airlines Corp. ⁽¹⁾	335,000	\$ 704,817
		\$ 704,817
Auto Components 0.4%		
Aisin Seiki Co., Ltd.	7,600	\$ 250,074
Cooper Tire and Rubber Co.	30,158	236,439
Denso Corp.	83,300	2,873,839
Johnson Controls, Inc.	114,456	3,282,598
NGK Spark Plug Co., Ltd.	20,000	230,598
Stanley Electric Co., Ltd.	17,200	417,701
Toyoda Gosei Co., Ltd.	5,900	172,954
Toyota Industries Corp.	9,000	289,453
		\$ 7,753,656
Automobiles 1.6%		
DaimlerChrysler AG	188,560	\$ 11,703,744
Harley-Davidson, Inc.	45,565	1,652,187
Honda Motor Co., Ltd.	129,800	4,437,163
Isuzu Motors, Ltd.	59,000	284,597
Suzuki Motor Corp.	60,100	1,425,859
Toyota Motor Corp.	84,207	3,981,658
Volkswagen AG	21,183	6,122,946
Volkswagen AG (Preference Shares)	3,759	544,710
		\$ 30,152,864

Security	Shares	Value
Beverages 1.2%		
Carlsberg A/S, Class B	8,103	\$ 781,079
Coca-Cola Co. (The)	19,951	1,037,053
Heineken NV	30,199	1,538,915

Kirin Holdings Co., Ltd. 83,000 1,300,100 Pepsi Bottling Group, Inc. 19,042 531,653 PepsiCo, Inc. 140,963 8,963,837 Pernod-Ricard SA 16,230 1,657,344 SABMiller PLC 136,622 3,118,740 Sapporo Holdings, Ltd. 160,000 1,122,101 Takara Holdings, Inc. 137,000 862,059 Takara Holdings, Inc. \$21,509,331 5 Biotechnology 2.3% \$764,039 4 Amgen, Inc. ⁽¹⁾ 16,201 \$764,039 4 Amgen, Inc. ⁽¹⁾ 95,284 5,325,423 5 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 5 Gelgene Corp. ⁽¹⁾ 98,231 6,274,014 5 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 6 Gelgene Corp. ⁽¹⁾ 98,231 6,274,014 5 Celgene Corp. ⁽¹⁾ 98,035 2,057,853 5 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 6 Gilead Sciences, Inc. ⁽¹⁾ 20,0				
Prepis Bottling Group, Inc. 19,042 531,653 PepsiCo, Inc. 140,963 8,963,837 Pernod-Ricard SA 16,230 1,657,344 SABMiller PLC 136,622 3,118,740 Sappor Holdings, Ltd. 160,000 1,122,101 Fakra Holdings, Inc. 137,000 862,059 Biotechnology 2.3% \$ 21,509,331 Biotechnology 2.3% \$ 23,6511 927,014 Biogen Idec, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 98,231 6,274,014 Celpene Corp. ⁽¹⁾ 98,231 6,274,014 Celpene Corp. ⁽¹⁾ 98,231 6,274,014 Celpalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 30,040 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 124,547 1,798,459 Sequeron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Set 42,033,540 80,000 327,059 Building Products 0.2% \$ 42,033,540 Buildiags Co., Ltd. 80,000	Ito En, Ltd.	37,800	596,450	
PepsiCo, Inc. 140,963 8,963,837 Permod-Ricard SA 16,230 1,657,344 SABMiller PLC 136,622 3,118,740 Sapporo Holdings, Ltd. 160,000 1,122,101 Takara Holdings, Inc. 137,000 862,059 Biotechnology 2.3% \$ 21,509,331 Biotechnology 2.3% \$ 764,039 Amgen, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 30,0857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 30,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 20,000 809,200 Marek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 St 42,033,540 St 42,033,540 St 42,033,540 Building Products 0.2% St	Kirin Holdings Co., Ltd.	83,000	1,300,100	
Pernod-Ricard SA 16.230 1.657,344 SABMiller PLC 136,622 3,118,740 Sapporo Holdings, Ltd. 160,000 1,122,101 Takara Holdings, Inc. 137,000 862,059 Sapporo Holdings, Inc. \$21,509,331 Biotechnology 2.3% \$21,509,331 Amgen, Inc. ⁽¹⁾ 16,201 \$764,039 Anylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Building Products 0.2% \$42,033,540 Building Products 0.2% \$3,889,115 Central Glass Co., Ltd. 156,497 \$1,897,917 Central Glass Co., Ltd. 86,000 326,803	Pepsi Bottling Group, Inc.	19,042	531,653	
SABMiller PLC 136,622 3,118,740 Sapporo Holdings, Ltd. 160,000 1,122,101 Takara Holdings, Inc. 137,000 862,059 Biotechnology 2,3% \$ 21,509,331 Biotechnology 2,3% \$ 764,039 Amgen, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 36,511 927,014 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Celgene Corp. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regenero Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Building Products 0.2% \$ 42,033,500 Building Products 0.2% \$ 42,033,500 Sanhi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. \$ 5,600 408,291 Masco Corp. \$ 9,062 929,045	PepsiCo, Inc.	140,963	8,963,837	
Sapporo Holdings, Ltd. 160,000 1,122,101 Takara Holdings, Inc. 137,000 862,059 Biotechnology 2.3% \$ 21,509,331 Biotechnology 2.3%	Pernod-Ricard SA	16,230	1,657,344	
Takara Holdings, Inc. 137,000 862,059 Biotechnology 2.3% Arngen, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 50,000 408,9200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Stahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 156,497 \$ 1,897,917 Staroug Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanva Shutter Corp. 59,062 929,045 Sanva Shutter Corp. \$ 3,889,115 5 Capital Markets 2.0% \$ 3,889,115	SABMiller PLC	136,622	3,118,740	
Biotechnology 2.3% Amgen, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Suilding Products 0.2% \$ 42,033,540 Building Products 0.2% \$ 1,897,917 Central Glass Co., Ltd. 156,497 \$ 1,897,917 S Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. \$ 3,889,115 \$ 3,889,115 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 3,889,115	Sapporo Holdings, Ltd.	160,000	1,122,101	
Biotechnology 2.3% Amgen, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Stahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% 3 Charles Schwab Corp. (The) 126,879 1,117,119 <	Takara Holdings, Inc.	137,000	862,059	
Aragen, Inc. ⁽¹⁾ 16,201 \$ 764,039 Amylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Sulding Products 0.2% * * Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 8,0,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% 4,799,833 Charles Schwab Corp. (The) 126,879 <td></td> <td></td> <td>\$ 21,509,331</td>			\$ 21,509,331	
Anylin Pharmaceuticals, Inc. ⁽¹⁾ 36,511 927,014 Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Stabi Glass Co., Ltd. 156,497 \$ 42,033,540 Building Products 0.2% 327,059 S Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 \$ 1,117,119 Bank of New York Mellon Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investo	Biotechnology 2.3%			
Biogen Idec, Inc. ⁽¹⁾ 95,284 5,325,423 Celgene Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Stabi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B </td <td>Amgen, Inc.⁽¹⁾</td> <td>16,201</td> <td>\$ 764,039</td>	Amgen, Inc. ⁽¹⁾	16,201	\$ 764,039	
Celegie Corp. ⁽¹⁾ 98,231 6,274,014 Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Building Products 0.2% 42,033,540 Building Products 0.2% 42,033,540 Stahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 actial Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B	Amylin Pharmaceuticals, Inc. ⁽¹⁾	36,511	927,014	
Cephalon, Inc. ⁽¹⁾ 30,857 2,057,853 CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Building Products 0.2% \$ 42,033,540 Building Products 0.2% \$ 42,033,540 Building Products 0.2% \$ 1,897,917 Central Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 \$ 1,117,119 Bank of New York Mellon Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc.	Biogen Idec, Inc. ⁽¹⁾	95,284	5,325,423	
CV Therapeutics, Inc. ⁽¹⁾ 50,000 411,500 Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 s 42,033,540 \$42,033,540 Building Products 0.2% \$42,033,540 Building Products 0.2% \$1,897,917 Central Glass Co., Ltd. 156,497 \$1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Sanwa Shutter Corp. \$3,889,115 \$3,889,115 Capital Markets 2.0% \$1,117,119 Bank of New York Mellon Corp. (The) 126,879 \$1,117,119 Bank of New York Mellon Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B </td <td>Celgene Corp.⁽¹⁾</td> <td>98,231</td> <td>6,274,014</td>	Celgene Corp. ⁽¹⁾	98,231	6,274,014	
Gilead Sciences, Inc. ⁽¹⁾ 439,064 23,248,439 ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 Stability Products 0.2% \$42,033,540 Building Products 0.2% \$1,897,917 Asahi Glass Co., Ltd. 156,497 \$1,897,917 Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$3,889,115 Capital Markets 2.0% \$1,117,119 Bank of New York Mellon Corp. (The) 126,879 \$1,117,119 Bank of New York Mellon Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Cephalon, Inc. ⁽¹⁾	30,857	2,057,853	
ImClone Systems, Inc. ⁽¹⁾ 20,000 809,200 Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 \$ 42,033,540 \$ 42,033,540 Building Products 0.2% \$ 156,497 \$ 1,897,917 Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	CV Therapeutics, Inc. ⁽¹⁾	50,000	411,500	
Martek Biosciences Corp. ⁽¹⁾ 12,388 417,599 Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 \$ 42,033,540 \$ 42,033,540 Building Products 0.2% \$ 1,897,917 Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 IS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Framework, Inc. 43,596 3,995,573	Gilead Sciences, Inc. ⁽¹⁾	439,064	23,248,439	
Regeneron Pharmaceuticals, Inc. ⁽¹⁾ 124,547 1,798,459 8 \$ 42,033,540 Building Products 0.2% Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Sarawa Shutter Corp. 86,000 326,803 Sarawa Shutter S 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	ImClone Systems, Inc. ⁽¹⁾	20,000	809,200	
\$ 42,033,540 Building Products 0.2% Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Martek Biosciences Corp. ⁽¹⁾	12,388	417,599	
Building Products 0.2% Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Regeneron Pharmaceuticals, Inc. ⁽¹⁾	124,547	1,798,459	
Asahi Glass Co., Ltd. 156,497 \$ 1,897,917 Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$ 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Federated Investors, Inc., Class B 15,936 548,517			\$ 42,033,540	
Central Glass Co., Ltd. 80,000 327,059 JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$3,889,115 Capital Markets 2.0% \$4,799,833 Charles Schwab Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Building Products 0.2%			
JS Group Corp. 25,600 408,291 Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 Sanwa Shutter Corp. 86,000 326,803 Capital Markets 2.0% \$3,889,115 Capital Markets 2.0% \$1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Asahi Glass Co., Ltd.	156,497	\$ 1,897,917	
Masco Corp. 59,062 929,045 Sanwa Shutter Corp. 86,000 326,803 \$ 3,889,115 3,889,115 Capital Markets 2.0% \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Central Glass Co., Ltd.	80,000	327,059	
Sanwa Shutter Corp. 86,000 326,803 \$ 3,889,115 Capital Markets 2.0% American Capital Strategies, Ltd. 46,997 \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Tensor Schwab Inc. 43,596 3,995,573	JS Group Corp.	25,600	408,291	
\$ 3,889,115 Capital Markets 2.0% American Capital Strategies, Ltd. 46,997 \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Masco Corp.	59,062	929,045	
Capital Markets 2.0% American Capital Strategies, Ltd. 46,997 \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Sanwa Shutter Corp.	86,000	326,803	
American Capital Strategies, Ltd. 46,997 \$ 1,117,119 Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573			\$ 3,889,115	
Bank of New York Mellon Corp. (The) 126,879 4,799,833 Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Capital Markets 2.0%			
Charles Schwab Corp. (The) 56,270 1,155,786 Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	American Capital Strategies, Ltd.	46,997	\$ 1,117,119	
Daiwa Securities Group, Inc. 113,000 1,040,889 Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Bank of New York Mellon Corp. (The)	126,879	4,799,833	
Federated Investors, Inc., Class B 15,936 548,517 Franklin Resources, Inc. 43,596 3,995,573	Charles Schwab Corp. (The)	56,270	1,155,786	
Franklin Resources, Inc. 43,596 3,995,573	Daiwa Securities Group, Inc.	113,000	1,040,889	
	Federated Investors, Inc., Class B	15,936	548,517	
Goldman Sachs Group, Inc. 31,002 5,422,250	Franklin Resources, Inc.	43,596	3,995,573	
	Goldman Sachs Group, Inc.	31,002	5,422,250	

See notes to financial statements 4

PORTFOLIO OF INVESTMENTS (Unaudited) CONT'D

Security	Shares	Value
Capital Markets (continued)		
Jafco Co., Ltd.	3,200	\$ 109,747
Merrill Lynch & Co., Inc.	85,000	2,695,350
Morgan Stanley	36,593	1,319,910
Nomura Holdings, Inc.	89,400	1,326,116
Northern Trust Corp.	66,797	4,580,270
Shinko Securities Co., Ltd.	107,000	316,016
UBS AG ⁽¹⁾	367,577	7,681,841
		\$ 36,109,217
Chemicals 2.0%		
Air Products and Chemicals, Inc.	9,559	\$ 945,003
BASF AG	249,622	17,216,295
Daicel Chemical Industries, Ltd.	62,000	349,836
Dainippon Ink and Chemicals, Inc.	120,000	348,828
Dow Chemical Co. (The)	73,566	2,568,189
E.I. Du Pont de Nemours & Co.	19,328	828,978
Eastman Chemical Co.	11,375	783,282
Ecolab, Inc.	22,890	984,041
Kaneka Corp.	154,000	1,050,817
Kansai Paint Co., Ltd.	86,000	596,517
Mitsubishi Chemical Holdings Corp.	35,000	204,151
Mitsubishi Rayon Co., Ltd.	273,000	862,569
Monsanto Co.	27,285	3,449,915
Nippon Shokubai Co., Ltd.	138,000	991,637
Nissan Chemical Industries, Ltd.	61,000	751,921
Nitto Denko Corp.	5,000	192,528
Rohm and Haas Co.	12,829	595,779
Shin-Etsu Chemical Co., Ltd.	61,500	3,822,867
Sumitomo Bakelite Co., Ltd.	39,000	213,055
Taiyo Nippon Sanso Corp.	72,000	601,767
		\$ 37,357,975
Commercial Banks 6.0%		
Banco Santander Central Hispano SA	981,734	\$ 17,923,331
Bank of Yokohama, Ltd.	113,000	782,753
Barclays PLC	1,068,873	6,059,090
Bayerische Hypo-Und Vereinsbank AG ⁽¹⁾	7,807	496,157
BB&T Corp.	82,529	1,879,185
BNP Paribas SA	142,080	12,798,525
Credit Agricole SA	152,288	3,093,664
DnB NOR ASA	105,036	1,334,327
Fifth Third Bancorp	132,860	1,352,515

Commercial Banks (continued)		
HBOS PLC	367,873	\$ 2,012,331
HSBC Holdings PLC	1,570,038	24,154,263
Intesa Sanpaolo RNC	182,000	938,468
Intesa Sanpaolo SpA	1,291,944	7,349,620
Joyo Bank, Ltd.	37,000	180,496
KeyCorp	55,394	608,226
Lloyds TSB Group PLC	970,946	5,951,963
Marshall & Ilsley Corp.	36,714	562,826
Mitsui Trust Holdings, Inc.	145,000	865,114
Natixis	48,829	537,877
Popular, Inc.	28,772	189,607
Regions Financial Corp.	39,761	433,793
Resona Holdings, Inc.	445	684,650
Royal Bank of Scotland PLC	343,985	1,463,151
Societe Generale	116,380	10,097,065
Sumitomo Trust and Banking Co., Ltd.	150,955	1,056,381
Synovus Financial Corp.	77,625	677,666
UniCredit SpA	522,068	3,177,875
Wachovia Corp.	33,000	512,490
Wells Fargo & Co.	110,189	2,616,989
Zions Bancorporation	25,092	790,147
		\$ 110,580,545
Commercial Services & Supplies 1.0%		
Adecco SA	11,692	\$ 579,633
Avery Dennison Corp.	23,372	1,026,732
Dai Nippon Printing Co., Ltd.	51,000	752,105
Equifax, Inc.	15,217	511,596
Half (Robert) International, Inc.	36,951	885,715
Manpower, Inc.	23,198	1,351,052
Randstad Holdings NV	17,043	593,542
Rentokil Initial PLC	2,511,211	4,942,037
RR Donnelley & Sons Co.	70,366	2,089,167
SECOM Co., Ltd.	69,300	3,381,210
Serco Group PLC	144,136	1,277,961
Waste Management, Inc.	18,690	704,800
		\$ 18,095,550
Communications Equipment 4.8%		
Cisco Systems, Inc. ⁽¹⁾	999,233	\$ 23,242,160
Corning, Inc.	13,370	308,179
Harris Corp.	47,813	2,414,078

See notes to financial statements 5

PORTFOLIO OF INVESTMENTS (Unaudited) CONT'D

Security	Shares	Value
Communications Equipment (continued)		
Nokia Oyj	434,865	\$ 10,612,998
QUALCOMM, Inc.	724,882	32,163,014
Research In Motion, Ltd. ⁽¹⁾	167,739	19,608,689
Riverbed Technology, Inc. ⁽¹⁾	15,921	218,436
		\$ 88,567,554
Computer Peripherals 5.5%		
Apple, Inc. ⁽¹⁾	411,813	\$ 68,953,969
Brocade Communications Systems, Inc. ⁽¹⁾	76,415	629,660
EMC Corp. ⁽¹⁾	279,905	4,111,804
Fujitsu, Ltd.	153,121	1,138,980
Hewlett-Packard Co.	247,871	10,958,377
International Business Machines Corp.	81,602	9,672,285
Mitsumi Electric Co., Ltd.	20,400	455,590
NEC Corp.	168,000	883,575
NetApp, Inc. ⁽¹⁾	24,665	534,244
Palm, Inc.	54,994	296,418
SanDisk Corp. ⁽¹⁾	53,957	1,008,996
Seagate Technology	85,910	1,643,458
Toshiba Corp.	187,431	1,385,128
		\$ 101,672,484
Construction & Engineering 0.2%		
Amec PLC	74,000	\$ 1,302,868
JGC Corp.	64,000	1,262,407
Obayashi Corp.	241,000	1,094,133
Skanska AB	43,000	614,004
		\$ 4,273,412
Construction Materials 0.3%		
Cemex SAB de CV ADR ⁽¹⁾	88,811	\$ 2,193,632
Lafarge SA	10,540	1,608,337
Vulcan Materials Co.	27,988	1,673,123
		\$ 5,475,092
Consumer Finance 0.2%		
Cattles PLC	141,322	\$ 374,116
Credit Saison Co., Ltd.	63,000	1,323,774
Mitsubishi UFJ Nicos Co., Ltd. ⁽¹⁾	38,000	125,928
Student Loan Corp.	16,049	1,574,086
		\$ 3,397,904

Security	Shares	Value
Containers & Packaging 0.1%		
Bemis Co., Inc.	21,337	\$ 478,376
Toyo Seikan Kaisha, Ltd.	71,300	1,260,844

		\$ 1,739,220
Distributors 0.1%		
Genuine Parts Co.	56,294	\$ 2,233,746
		\$ 2,233,746
Diversified Consumer Services 0.1%		
Corinthian Colleges, Inc. ⁽¹⁾	48,836	\$ 566,986
H&R Block, Inc.	65,199	1,395,259
Regis Corp.	10,423	274,646
		\$ 2,236,891
Diversified Financial Services 1.6%		
Bank of America Corp.	270,451	\$ 6,455,665
CITGroup, Inc.	59,215	403,254
Citigroup, Inc.	39,613	663,914
CME Group, Inc.	6,433	2,465,061
Fortis	166,380	2,644,695
ING Groep NV	317,107	10,033,170
Investor AB, Class B	78,000	1,639,498
JPMorgan Chase & Co.		